866-997-4948(US-Canada Toll Free)

Neuropathic Pain - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 561 Pages

Neuropathic Pain - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuropathic Pain Pipeline Review, H2 2016, provides an overview of the Neuropathic Pain (Central Nervous System) pipeline landscape.

Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury. The nerve fibres could be damaged resulting in the generation of abnormal signals. Neuropathic pain is also exhibited along with many other diseases. The symptoms might include shooting pain and numbness. Several factors are involved in causing neuropathic pain however there seems to be no specific reason. Trauma, kidney disease, alcoholism, infections, stress etc may lead to painful symptoms. The condition may be controlled by the use of medications and psychological therapies.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuropathic Pain Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Neuropathic Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 6, 27, 29, 1, 119, 21 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 37 and 1 molecules, respectively.

Neuropathic Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neuropathic Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Neuropathic Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neuropathic Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neuropathic Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neuropathic Pain (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neuropathic Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neuropathic Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 8
Neuropathic Pain Overview 9
Therapeutics Development 10
Neuropathic Pain - Therapeutics under Development by Companies 12
Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes 22
Neuropathic Pain - Pipeline Products Glance 24
Neuropathic Pain - Products under Development by Companies 28
Neuropathic Pain - Products under Investigation by Universities/Institutes 42
Neuropathic Pain - Companies Involved in Therapeutics Development 44
Neuropathic Pain - Therapeutics Assessment 165
Drug Profiles 188
Neuropathic Pain - Dormant Projects 491
Neuropathic Pain - Discontinued Products 516
Neuropathic Pain - Product Development Milestones 524
Appendix 534

List of Tables
Number of Products under Development for Neuropathic Pain, H2 2016 36
Number of Products under Development for Neuropathic Pain - Comparative Analysis, H2 2016 37
Number of Products under Development by Companies, H2 2016 38
Number of Products under Development by Companies, H2 2016 (Contd..1) 39
Number of Products under Development by Companies, H2 2016 (Contd..2) 40
Number of Products under Development by Companies, H2 2016 (Contd..3) 41
Number of Products under Development by Companies, H2 2016 (Contd..4) 42
Number of Products under Development by Companies, H2 2016 (Contd..5) 43
Number of Products under Development by Companies, H2 2016 (Contd..6) 44
Number of Products under Development by Companies, H2 2016 (Contd..7) 45
Number of Products under Development by Companies, H2 2016 (Contd..8) 46
Number of Products under Development by Companies, H2 2016 (Contd..9) 47
Number of Products under Investigation by Universities/Institutes, H2 2016 48
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 49
Comparative Analysis by Late Stage Development, H2 2016 50
Comparative Analysis by Clinical Stage Development, H2 2016 51
Comparative Analysis by Early Stage Development, H2 2016 52
Comparative Analysis by Unknown Stage Development, H2 2016 53
Products under Development by Companies, H2 2016 54
Products under Development by Companies, H2 2016 (Contd..1) 55
Products under Development by Companies, H2 2016 (Contd..2) 56
Products under Development by Companies, H2 2016 (Contd..3) 57
Products under Development by Companies, H2 2016 (Contd..4) 58
Products under Development by Companies, H2 2016 (Contd..5) 59
Products under Development by Companies, H2 2016 (Contd..6) 60
Products under Development by Companies, H2 2016 (Contd..7) 61
Products under Development by Companies, H2 2016 (Contd..8) 62
Products under Development by Companies, H2 2016 (Contd..9) 63
Products under Development by Companies, H2 2016 (Contd..10) 64
Products under Development by Companies, H2 2016 (Contd..11) 65
Products under Development by Companies, H2 2016 (Contd..12) 66
Products under Development by Companies, H2 2016 (Contd..13) 67
Products under Investigation by Universities/Institutes, H2 2016 68
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 69
Neuropathic Pain - Pipeline by 2-BBB Medicines BV, H2 2016 70
Neuropathic Pain - Pipeline by AbbVie Inc, H2 2016 71
Neuropathic Pain - Pipeline by Acadia Pharmaceuticals Inc, H2 2016 72
Neuropathic Pain - Pipeline by Achelios Therapeutics Inc, H2 2016 73
Neuropathic Pain - Pipeline by Adynxx Inc, H2 2016 74
Neuropathic Pain - Pipeline by Aevi Genomic Medicine Inc, H2 2016 75
Neuropathic Pain - Pipeline by Affectis Pharmaceuticals AG, H2 2016 76
Neuropathic Pain - Pipeline by Amura Holdings Ltd, H2 2016 77
Neuropathic Pain - Pipeline by AnaBios Corp, H2 2016 78
Neuropathic Pain - Pipeline by Anavex Life Sciences Corp, H2 2016 79
Neuropathic Pain - Pipeline by AngioChem Inc, H2 2016 80
Neuropathic Pain - Pipeline by APT Therapeutics Inc, H2 2016 81
Neuropathic Pain - Pipeline by Aquilus Pharmaceuticals Inc, H2 2016 82
Neuropathic Pain - Pipeline by Araim Pharmaceuticals Inc, H2 2016 83
Neuropathic Pain - Pipeline by Arena Pharmaceuticals Inc, H2 2016 84
Neuropathic Pain - Pipeline by Asahi Kasei Pharma Corp, H2 2016 85
Neuropathic Pain - Pipeline by Astellas Pharma Inc, H2 2016 86
Neuropathic Pain - Pipeline by AstraZeneca Plc, H2 2016 87
Neuropathic Pain - Pipeline by BCI Pharma, H2 2016 88
Neuropathic Pain - Pipeline by Biogen Inc, H2 2016 89
Neuropathic Pain - Pipeline by BioLineRx Ltd, H2 2016 90
Neuropathic Pain - Pipeline by Biomar Microbial Technologies, H2 2016 91
Neuropathic Pain - Pipeline by Bionomics Ltd, H2 2016 92
Neuropathic Pain - Pipeline by Bristol-Myers Squibb Company, H2 2016 93
Neuropathic Pain - Pipeline by Can-Fite BioPharma Ltd, H2 2016 94
Neuropathic Pain - Pipeline by Cara Therapeutics Inc, H2 2016 95
Neuropathic Pain - Pipeline by Catalyst Biosciences Inc, H2 2016 96
Neuropathic Pain - Pipeline by Cavion LLC, H2 2016 97
Neuropathic Pain - Pipeline by Centrexion Therapeutics Corp, H2 2016 98
Neuropathic Pain - Pipeline by Cerecor Inc, H2 2016 99
Neuropathic Pain - Pipeline by Chromocell Corp, H2 2016 100
Neuropathic Pain - Pipeline by Circuit Therapeutics Inc, H2 2016 101
Neuropathic Pain - Pipeline by CLL Pharma SA, H2 2016 102
Neuropathic Pain - Pipeline by Colby Pharmaceutical Company, H2 2016 103
Neuropathic Pain - Pipeline by ContraVir Pharmaceuticals Inc, H2 2016 104
Neuropathic Pain - Pipeline by Crinetics Pharmaceuticals Inc, H2 2016 105
Neuropathic Pain - Pipeline by Cytogel Pharma LLC, H2 2016 106
Neuropathic Pain - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016 107
Neuropathic Pain - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 108
Neuropathic Pain - Pipeline by Develco Pharma Schweiz AG, H2 2016 109
Neuropathic Pain - Pipeline by Dompe Farmaceutici SpA, H2 2016 110
Neuropathic Pain - Pipeline by Eisai Co Ltd, H2 2016 111
Neuropathic Pain - Pipeline by Eli Lilly and Company, H2 2016 112
Neuropathic Pain - Pipeline by Endece LLC, H2 2016 113
Neuropathic Pain - Pipeline by Evec Inc, H2 2016 114
Neuropathic Pain - Pipeline by Genecode AS, H2 2016 115
Neuropathic Pain - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2016 116
Neuropathic Pain - Pipeline by Glialogix Inc, H2 2016 117
Neuropathic Pain - Pipeline by Grunenthal GmbH, H2 2016 118
Neuropathic Pain - Pipeline by GW Pharmaceuticals Plc, H2 2016 119
Neuropathic Pain - Pipeline by Hydra Biosciences Inc, H2 2016 120
Neuropathic Pain - Pipeline by Immune Pharmaceuticals Inc, H2 2016 121
Neuropathic Pain - Pipeline by Inpellis Inc, H2 2016 122
Neuropathic Pain - Pipeline by Integral Molecular Inc, H2 2016 123
Neuropathic Pain - Pipeline by Intellipharmaceutics International Inc, H2 2016 124
Neuropathic Pain - Pipeline by iX Biopharma Ltd, H2 2016 125
Neuropathic Pain - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 126
Neuropathic Pain - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016 127
Neuropathic Pain - Pipeline by Jiangsu Nhwa Pharmaceutical Corp Ltd, H2 2016 128
Neuropathic Pain - Pipeline by Johnson & Johnson, H2 2016 129
Neuropathic Pain - Pipeline by Kareus Therapeutics SA, H2 2016 130
Neuropathic Pain - Pipeline by Knopp Biosciences LLC, H2 2016 131
Neuropathic Pain - Pipeline by Kolon Life Science Inc, H2 2016 132
Neuropathic Pain - Pipeline by KPI Therapeutics Inc, H2 2016 133
Neuropathic Pain - Pipeline by Laboratorios Del Dr Esteve SA, H2 2016 134
Neuropathic Pain - Pipeline by Lexicon Pharmaceuticals Inc, H2 2016 135
Neuropathic Pain - Pipeline by Lohocla Research Corp, H2 2016 136
Neuropathic Pain - Pipeline by Lpath Inc, H2 2016 137
Neuropathic Pain - Pipeline by Mapi Pharma Ltd, H2 2016 138
Neuropathic Pain - Pipeline by Medestea Research & Production SpA, H2 2016 139
Neuropathic Pain - Pipeline by Medifron DBT Co Ltd, H2 2016 140
Neuropathic Pain - Pipeline by Medisyn Technologies Inc, H2 2016 141
Neuropathic Pain - Pipeline by Medy-Tox Inc, H2 2016 142
Neuropathic Pain - Pipeline by Merck & Co Inc, H2 2016 143
Neuropathic Pain - Pipeline by Nanomerics Ltd, H2 2016 144
Neuropathic Pain - Pipeline by Neurim Pharmaceuticals Ltd, H2 2016 145
Neuropathic Pain - Pipeline by Neurocentrx Pharma Ltd, H2 2016 146
Neuropathic Pain - Pipeline by NeuroCycle Therapeutics GmbH, H2 2016 147
Neuropathic Pain - Pipeline by NeuroMax, H2 2016 148
Neuropathic Pain - Pipeline by NeurOp Inc, H2 2016 149
Neuropathic Pain - Pipeline by Newron Pharmaceuticals SpA, H2 2016 150
Neuropathic Pain - Pipeline by Nippon Chemiphar Co Ltd, H2 2016 151
Neuropathic Pain - Pipeline by NoNO Inc, H2 2016 152
Neuropathic Pain - Pipeline by Novaremed Ltd, H2 2016 153
Neuropathic Pain - Pipeline by Novartis AG, H2 2016 154
Neuropathic Pain - Pipeline by NsGene A/S, H2 2016 155
Neuropathic Pain - Pipeline by Omeros Corp, H2 2016 156
Neuropathic Pain - Pipeline by Orion Oyj, H2 2016 157
Neuropathic Pain - Pipeline by Patagonia Pharmaceuticals LLC, H2 2016 158
Neuropathic Pain - Pipeline by PeriphaGen Inc, H2 2016 159
Neuropathic Pain - Pipeline by Pfizer Inc, H2 2016 160
Neuropathic Pain - Pipeline by Pharmaleads SA, H2 2016 161
Neuropathic Pain - Pipeline by PharmEste Srl, H2 2016 162
Neuropathic Pain - Pipeline by Phosphagenics Ltd, H2 2016 163
Neuropathic Pain - Pipeline by Prismic Pharmaceuticals Inc, H2 2016 164
Neuropathic Pain - Pipeline by RaQualia Pharma Inc, H2 2016 165
Neuropathic Pain - Pipeline by Re-Pharm Ltd, H2 2016 166
Neuropathic Pain - Pipeline by Relmada Therapeutics Inc, H2 2016 167
Neuropathic Pain - Pipeline by Revance Therapeutics Inc, H2 2016 168
Neuropathic Pain - Pipeline by Saniona AB, H2 2016 169
Neuropathic Pain - Pipeline by Scilex Pharmaceuticals Inc, H2 2016 170
Neuropathic Pain - Pipeline by Shionogi & Co Ltd, H2 2016 171
Neuropathic Pain - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2016 172
Neuropathic Pain - Pipeline by Sphaera Pharma Pvt Ltd, H2 2016 173
Neuropathic Pain - Pipeline by Spherium Biomed SL, H2 2016 174
Neuropathic Pain - Pipeline by Sunovion Pharmaceuticals Inc, H2 2016 175
Neuropathic Pain - Pipeline by Syntrix Biosystems Inc, H2 2016 176
Neuropathic Pain - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 177
Neuropathic Pain - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 178
Neuropathic Pain - Pipeline by Theranexus SAS, H2 2016 179
Neuropathic Pain - Pipeline by Theravasc Inc, H2 2016 180
Neuropathic Pain - Pipeline by Toray Industries Inc, H2 2016 181
Neuropathic Pain - Pipeline by Torrent Pharmaceuticals Ltd, H2 2016 182
Neuropathic Pain - Pipeline by Trevena Inc, H2 2016 183
Neuropathic Pain - Pipeline by Trigemina Inc, H2 2016 184
Neuropathic Pain - Pipeline by Virobay Inc, H2 2016 185
Neuropathic Pain - Pipeline by VistaGen Therapeutics Inc, H2 2016 186
Neuropathic Pain - Pipeline by Vitality Biopharma Inc, H2 2016 187
Neuropathic Pain - Pipeline by Yuhan Corp, H2 2016 188
Neuropathic Pain - Pipeline by Yungjin Pharm Co Ltd, H2 2016 189
Neuropathic Pain - Pipeline by Zynerba Pharmaceuticals Inc, H2 2016 190
Assessment by Monotherapy Products, H2 2016 191
Assessment by Combination Products, H2 2016 192
Number of Products by Stage and Target, H2 2016 194
Number of Products by Stage and Mechanism of Action, H2 2016 202
Number of Products by Stage and Route of Administration, H2 2016 211
Number of Products by Stage and Molecule Type, H2 2016 213
Neuropathic Pain - Dormant Projects, H2 2016 517
Neuropathic Pain - Dormant Projects (Contd..1), H2 2016 518
Neuropathic Pain - Dormant Projects (Contd..2), H2 2016 519
Neuropathic Pain - Dormant Projects (Contd..3), H2 2016 520
Neuropathic Pain - Dormant Projects (Contd..4), H2 2016 521
Neuropathic Pain - Dormant Projects (Contd..5), H2 2016 522
Neuropathic Pain - Dormant Projects (Contd..6), H2 2016 523
Neuropathic Pain - Dormant Projects (Contd..7), H2 2016 524
Neuropathic Pain - Dormant Projects (Contd..8), H2 2016 525
Neuropathic Pain - Dormant Projects (Contd..9), H2 2016 526
Neuropathic Pain - Dormant Projects (Contd..10), H2 2016 527
Neuropathic Pain - Dormant Projects (Contd..11), H2 2016 528
Neuropathic Pain - Dormant Projects (Contd..12), H2 2016 529
Neuropathic Pain - Dormant Projects (Contd..13), H2 2016 530
Neuropathic Pain - Dormant Projects (Contd..14), H2 2016 531
Neuropathic Pain - Dormant Projects (Contd..15), H2 2016 532
Neuropathic Pain - Dormant Projects (Contd..16), H2 2016 533
Neuropathic Pain - Dormant Projects (Contd..17), H2 2016 534
Neuropathic Pain - Dormant Projects (Contd..18), H2 2016 535
Neuropathic Pain - Dormant Projects (Contd..19), H2 2016 536
Neuropathic Pain - Dormant Projects (Contd..20), H2 2016 537
Neuropathic Pain - Dormant Projects (Contd..21), H2 2016 538
Neuropathic Pain - Dormant Projects (Contd..22), H2 2016 539
Neuropathic Pain - Dormant Projects (Contd..23), H2 2016 540
Neuropathic Pain - Dormant Projects (Contd..24), H2 2016 541
Neuropathic Pain - Discontinued Products, H2 2016 542
Neuropathic Pain - Discontinued Products (Contd..1), H2 2016 543
Neuropathic Pain - Discontinued Products (Contd..2), H2 2016 544
Neuropathic Pain - Discontinued Products (Contd..3), H2 2016 545
Neuropathic Pain - Discontinued Products (Contd..4), H2 2016 546
Neuropathic Pain - Discontinued Products (Contd..5), H2 2016 547
Neuropathic Pain - Discontinued Products (Contd..6), H2 2016 548
Neuropathic Pain - Discontinued Products (Contd..7), H2 2016 549

List of Figures
Number of Products under Development for Neuropathic Pain, H2 2016 36
Number of Products under Development for Neuropathic Pain - Comparative Analysis, H2 2016 37
Number of Products under Development by Companies, H2 2016 38
Number of Products under Investigation by Universities/Institutes, H2 2016 48
Comparative Analysis by Late Stage Development, H2 2016 50
Comparative Analysis by Clinical Stage Development, H2 2016 51
Comparative Analysis by Early Stage Products, H2 2016 52
Assessment by Monotherapy Products, H2 2016 191
Assessment by Combination Products, H2 2016 192
Number of Products by Top 10 Targets, H2 2016 193
Number of Products by Stage and Top 10 Targets, H2 2016 193
Number of Products by Top 10 Mechanism of Actions, H2 2016 201
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 201
Number of Products by Top 10 Routes of Administration, H2 2016 210
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 210
Number of Products by Top 10 Molecule Types, H2 2016 212
Number of Products by Stage and Top 10 Molecule Types, H2 2016 212

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *